Extent of Signal Hyperintensity on Unenhanced T1-weighted Brain MR Images after More than 35 Administrations of Linear Gadolinium-based Contrast Agents.

Purpose To explore the extent of signal hyperintensity in the brain on unenhanced T1-weighted magnetic resonance (MR) images with increasing gadolinium-based contrast agent (GBCA) doses in patients who received 35 or more linear GBCA administrations. Materials and Methods In this institutional review board-approved HIPAA-compliant retrospective study, picture archiving and communication systems of two tertiary referral hospitals were searched to identify patients who received 35 or more linear GBCA administrations. Unenhanced T1-weighted images of the brain in patients after six, 12, and 24 GBCA administrations and after the final GBCA administration were independently reviewed by three radiologists to identify sites where T1 signal intensity was increasing. Areas identified by all three observers as increasing in T1 signal intensity when compared with baseline images were further analyzed with a quantitative region of interest analysis measuring the rate of signal increase per injection and the total change after 24 linear GBCA administrations relative to reference tissues that did not show T1 shortening. Results Qualitative analysis of 13 patients with 39-59 linear GBCA administrations showed visually detectable T1 shortening in the dentate nucleus (n = 13), globus pallidus (n = 13), substantia nigra (n = 13), posterior thalamus (n = 12), red nucleus (n = 10), colliculi (n = 10), superior cerebellar peduncle (n = 7), caudate nucleus (n = 4), whole thalamus (n = 3), and putamen (n = 2). Quantitative analysis enable confirmation of signal intensity increases on unenhanced T1-weighted images relative to reference tissues in the dentate nucleus (0.53% signal intensity increase per injection, P < .001), globus pallidus (0.23% increase, P = .009), posterior thalamus (0.26% increase, P < .001), substantia nigra (0.25% increase, P = .01), red nucleus (0.25% increase, P = .01), cerebellar peduncle (0.19% increase, P = .001), and colliculi (0.21% increase, P = .02). Conclusion Increased signal intensity on unenhanced T1-weighted images was seen in the posterior thalamus, substantia nigra, red nucleus, cerebellar peduncle, colliculi, dentate nucleus, and globus pallidus. © RSNA, 2016.

[1]  P. Lai,et al.  Hyperintense basal ganglia on T1-weighted MR imaging. , 1999, AJR. American journal of roentgenology.

[2]  À. Rovira,et al.  MR Imaging Findings in Hepatic Encephalopathy , 2008, American Journal of Neuroradiology.

[3]  S. Furui,et al.  Recent Advances in Understanding Gadolinium Retention in the Brain , 2016, American Journal of Neuroradiology.

[4]  David F Kallmes,et al.  Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. , 2015, Radiology.

[5]  C. Mallio,et al.  High T1 Signal Intensity in Dentate Nucleus after Multiple Injections of Linear Gadolinium Chelates. , 2015, Radiology.

[6]  Pascal J. Kieslich,et al.  Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration , 2015, Investigative radiology.

[7]  S. Aime,et al.  Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition , 2009, Journal of magnetic resonance imaging : JMRI.

[8]  S. Mirowitz,et al.  Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. , 1991, Radiology.

[9]  N. Karabulut.  Gadolinium deposition in the brain: another concern regarding gadolinium-based contrast agents. , 2015, Diagnostic and interventional radiology.

[10]  D. V. van Thiel,et al.  Chronic acquired hepatic failure: MR imaging of the brain at 1.5 T. , 1991, AJNR. American journal of neuroradiology.

[11]  V. Runge.  Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus , 2016, Investigative radiology.

[12]  J. Cheon,et al.  MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. , 2006, AJNR. American journal of neuroradiology.

[13]  R. Brasch,et al.  Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. , 1984, AJR. American journal of roentgenology.

[14]  J. Wardlaw,et al.  Identification of mineral deposits in the brain on radiological images: a systematic review , 2012, European Radiology.

[15]  M. Prince,et al.  Signal Change in the Dentate Nucleus on T1-Weighted MR Images After Multiple Administrations of Gadopentetate Dimeglumine Versus Gadobutrol. , 2016, AJR. American journal of roentgenology.

[16]  D. Stojanov,et al.  Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol , 2016, European Radiology.

[17]  Jeffrey H. Miller,et al.  MRI Brain Signal Intensity Changes of a Child During the Course of 35 Gadolinium Contrast Examinations , 2015, Pediatrics.

[18]  Shigeru Furui,et al.  High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. , 2015, Radiology.

[19]  Richard C. Semelka,et al.  High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. , 2015, Radiology.

[20]  Vincenzo Di Lazzaro,et al.  Progressive Increase of T1 Signal Intensity of the Dentate Nucleus on Unenhanced Magnetic Resonance Images Is Associated With Cumulative Doses of Intravenously Administered Gadodiamide in Patients With Normal Renal Function, Suggesting Dechelation , 2014, Investigative radiology.

[21]  C. Mallio,et al.  Gadodiamide and Dentate Nucleus T1 Hyperintensity in Patients With Meningioma Evaluated by Multiple Follow-Up Contrast-Enhanced Magnetic Resonance Examinations With No Systemic Interval Therapy. , 2015, Investigative radiology.

[22]  Shigeru Furui,et al.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. , 2015, Radiology.

[23]  Daisuke Takenaka,et al.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.

[24]  Dorothee P Auer,et al.  T1‐Weighted MRI shows stage‐dependent substantia nigra signal loss in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[25]  P. Hals,et al.  Biodistribution and toxicity of MR imaging contrast media , 1993, Journal of magnetic resonance imaging : JMRI.

[26]  A. Maia,et al.  A Preliminary Study Revealing a New Association in Patients Undergoing Maintenance Hemodialysis: Manganism Symptoms and T1 Hyperintense Changes in the Basal Ganglia , 2007, American Journal of Neuroradiology.

[27]  Pascal J. Kieslich,et al.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. , 2015, Radiology.

[28]  Yong Chul Shin,et al.  High signal intensity on magnetic resonance imaging as a predictor of neurobehavioral performance of workers exposed to manganese. , 2007, Neurotoxicology.

[29]  D. Yousem,et al.  Hyperintense Dentate Nuclei on T1-Weighted MRI: Relation to Repeat Gadolinium Administration , 2015, American Journal of Neuroradiology.